Skip to main content
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology 11/2007

01.11.2007 | Clinical Investigation

Bevacizumab (Avastin) treatment in patients with retinal angiomatous proliferation

verfasst von: Sandra Joeres, Florian M. A. Heussen, Tobias Treziak, Silvia Bopp, Antonia M. Joussen

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 11/2007

Einloggen, um Zugang zu erhalten

Abstract

Aim

To determine the anatomical and functional outcome after injection of bevacizumab (Avastin, Genentech) in eyes with retinal angiomatous proliferation (RAP).

Design

Prospective interventional case series.

Methods

Sixteen eyes of 16 consecutive patients with visual loss due to RAP underwent intravitreal injections of 1.25 mg (0.05 ml) bevacizumab. Best corrected visual acuity testing, fluorescein and ICG-angiography as well as OCT imaging were performed at baseline and at each follow-up visit within a 3-month period.

Results

Mean visual acuity pre-injection was 0.68 ± 0.36 logMAR (n = 16), mean reading ability 0.58 ± 0.26 logRAD (n = 11). Far vision increased significantly by a mean of 1.7 ± 2 lines 4 weeks after the injection (p = 0.004), as did reading (0.6 ± 2.3 lines, p > 0.05). Both remained stable up to 3 months. Central retinal thickness decreased from 367 ± 112 μm (mean±SD) to 272 ± 123 μm 3 months after injection (p = 0.006). Leakage decreased angiographically in 12 eyes (75%) and remained stable in four eyes (25%). Re-injection of bevacizumab within the 3-month follow-up period was performed once in eight eyes, and twice in one eye. No adverse events were observed.

Conclusion

Intravitreal bevacizumab (Avastin) resulted in a reduction of leakage, intra- and subretinal fluid. An increase in visual acuity was seen already 4 weeks after first injection. However, a complete occlusion of feeder vessels could not be achieved within this 3-month period. Randomized clinical trials would be required to evaluate dose and frequency of injections and possible beneficial effects of combination therapies, as well as the long-term results.
Literatur
1.
Zurück zum Zitat Kuhn D, Meunier I, Soubrane G et al (1995) Imaging of chorioretinal anastomoses in vascularized retinal pigment epithelium detachments. Arch Ophthalmol 11:1392–1398 Kuhn D, Meunier I, Soubrane G et al (1995) Imaging of chorioretinal anastomoses in vascularized retinal pigment epithelium detachments. Arch Ophthalmol 11:1392–1398
2.
Zurück zum Zitat Boscia F, Furino C, Sborgia L et al (2004) Photodynamic therapy for retinal angiomatous proliferations and pigment epithelium detachment. Am J Ophthalmol 138:1077–1079PubMedCrossRef Boscia F, Furino C, Sborgia L et al (2004) Photodynamic therapy for retinal angiomatous proliferations and pigment epithelium detachment. Am J Ophthalmol 138:1077–1079PubMedCrossRef
3.
Zurück zum Zitat Nicolo M, Ghiglione D, Lai S et al (2006) Retinal angiomatous proliferation treated by intravitreal triamcinolone and photodynamic therapy with verteporfin. Graefes Arch Clin Exp Ophthalmol 244:1336–1338PubMedCrossRef Nicolo M, Ghiglione D, Lai S et al (2006) Retinal angiomatous proliferation treated by intravitreal triamcinolone and photodynamic therapy with verteporfin. Graefes Arch Clin Exp Ophthalmol 244:1336–1338PubMedCrossRef
4.
Zurück zum Zitat Bottoni F, Romano M, Massacesi A et al (2006) Remodeling of the vascular channels in retinal angiomatous proliferations treated with intravitreal triamcinolone acetonide and photodynamic therapy. Graefes Arch Clin Exp Ophthalmol 244:1528–1533PubMedCrossRef Bottoni F, Romano M, Massacesi A et al (2006) Remodeling of the vascular channels in retinal angiomatous proliferations treated with intravitreal triamcinolone acetonide and photodynamic therapy. Graefes Arch Clin Exp Ophthalmol 244:1528–1533PubMedCrossRef
5.
Zurück zum Zitat Freund KB, Klais CM, Eandi CM et al (2006) Sequenced combined intravitreal triamcinolone and indocyanine green angiography-guided photodynamic therapy for retinal angiomatous proliferation. Arch Ophthalmol 124:487–492PubMedCrossRef Freund KB, Klais CM, Eandi CM et al (2006) Sequenced combined intravitreal triamcinolone and indocyanine green angiography-guided photodynamic therapy for retinal angiomatous proliferation. Arch Ophthalmol 124:487–492PubMedCrossRef
6.
Zurück zum Zitat Smithen LM, Ober MD, Maranan L et al (2004) Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol 138:740–743PubMedCrossRef Smithen LM, Ober MD, Maranan L et al (2004) Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol 138:740–743PubMedCrossRef
7.
Zurück zum Zitat Jonas J, Heatley G, Spaide R et al (2005) Intravitreal triamcinolone acetonide and secondary ocular hypertension. J Glaucoma 14:168–171PubMedCrossRef Jonas J, Heatley G, Spaide R et al (2005) Intravitreal triamcinolone acetonide and secondary ocular hypertension. J Glaucoma 14:168–171PubMedCrossRef
8.
Zurück zum Zitat Gragoudas ES, Adamis AP, Cunningham ET Jr et al (2004) VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351:2805–2816PubMedCrossRef Gragoudas ES, Adamis AP, Cunningham ET Jr et al (2004) VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351:2805–2816PubMedCrossRef
9.
Zurück zum Zitat Medienmitteilung Novartis. Preliminary data from second pivotal Phase III study showed Lucentis maintained or improved vision in 95 percent of patients with age-related macular degeneration. Basel, 7. November 2005 Medienmitteilung Novartis. Preliminary data from second pivotal Phase III study showed Lucentis maintained or improved vision in 95 percent of patients with age-related macular degeneration. Basel, 7. November 2005
10.
Zurück zum Zitat Spaide RF, Laud K, Fine HF et al (2006) Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26:383–390PubMedCrossRef Spaide RF, Laud K, Fine HF et al (2006) Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26:383–390PubMedCrossRef
11.
Zurück zum Zitat Yannuzzi LA, Negrao S, Iida T et al (2001) Retinal angiomatous proliferation in age-related macular degeneration. Retina 21:416–434PubMedCrossRef Yannuzzi LA, Negrao S, Iida T et al (2001) Retinal angiomatous proliferation in age-related macular degeneration. Retina 21:416–434PubMedCrossRef
12.
Zurück zum Zitat Radner W, Willinger U, Obermayer W et al (1998) Eine neue Lesetafel zur gleichzeitigen Bestimmung von Lesevisus und Lesegeschwindigkeit. Klin Monatsbl Augenheilkd 213:174–181PubMedCrossRef Radner W, Willinger U, Obermayer W et al (1998) Eine neue Lesetafel zur gleichzeitigen Bestimmung von Lesevisus und Lesegeschwindigkeit. Klin Monatsbl Augenheilkd 213:174–181PubMedCrossRef
13.
Zurück zum Zitat Stifter E, Konig F, Lang T et al (2004) Reliability of a standardized reading chart system: variance component analysis, test-retest and inter-chart reliability. Graefes Arch Clin Exp Ophthalmol 242:31–39PubMedCrossRef Stifter E, Konig F, Lang T et al (2004) Reliability of a standardized reading chart system: variance component analysis, test-retest and inter-chart reliability. Graefes Arch Clin Exp Ophthalmol 242:31–39PubMedCrossRef
14.
Zurück zum Zitat Schachat AP, Chambers WA, Liesegang TJ, Albert DA (2003) Safe and effective. Ophthalmology 110:2073–2074PubMedCrossRef Schachat AP, Chambers WA, Liesegang TJ, Albert DA (2003) Safe and effective. Ophthalmology 110:2073–2074PubMedCrossRef
15.
Zurück zum Zitat Slakter JS, Yannuzzi LA, Schneider U et al (2000) Retinal choroidal anastomoses and occult choroidal neovascularization in age-related macular degeneration. Ophthalmology 107:742–753PubMedCrossRef Slakter JS, Yannuzzi LA, Schneider U et al (2000) Retinal choroidal anastomoses and occult choroidal neovascularization in age-related macular degeneration. Ophthalmology 107:742–753PubMedCrossRef
16.
Zurück zum Zitat Klais CM, Eandi CM, Ober MD et al (2006) Anecortave acetate treatment for retinal angiomatous proliferation: a pilot study. Retina 26:773–779PubMedCrossRef Klais CM, Eandi CM, Ober MD et al (2006) Anecortave acetate treatment for retinal angiomatous proliferation: a pilot study. Retina 26:773–779PubMedCrossRef
17.
Zurück zum Zitat Lafaut BA, Aisenbrey S, Vanden Broecke C et al (2000) Clinicopathological correlation of deep retinal vascular anomalous complex in age related macular degeneration. Br J Ophthalmol 84(11):1269–1274PubMedCrossRef Lafaut BA, Aisenbrey S, Vanden Broecke C et al (2000) Clinicopathological correlation of deep retinal vascular anomalous complex in age related macular degeneration. Br J Ophthalmol 84(11):1269–1274PubMedCrossRef
18.
19.
Zurück zum Zitat Blaauwgeers HG, Holtkamp GM, Rutten H et al (1999) Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. Am J Pathol 155:421–428PubMed Blaauwgeers HG, Holtkamp GM, Rutten H et al (1999) Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. Am J Pathol 155:421–428PubMed
20.
Zurück zum Zitat Jablonski MM, Tombran-Tink J, Mrazek DA et al (2001) Pigment epithelium derived factor supports normal Muller cell development and glutamine synthetase expression after removal of the retinal pigment epithelium. Glia 35:14–25PubMedCrossRef Jablonski MM, Tombran-Tink J, Mrazek DA et al (2001) Pigment epithelium derived factor supports normal Muller cell development and glutamine synthetase expression after removal of the retinal pigment epithelium. Glia 35:14–25PubMedCrossRef
21.
Zurück zum Zitat Becerra SP, Fariss RN, Wu YQ et al (2004) Pigment epithelium-derived factor in the monkey retinal pigment epithelium and interphotoreceptor matrix: apical secretion and distribution. Exp Eye Res 78:223–234PubMedCrossRef Becerra SP, Fariss RN, Wu YQ et al (2004) Pigment epithelium-derived factor in the monkey retinal pigment epithelium and interphotoreceptor matrix: apical secretion and distribution. Exp Eye Res 78:223–234PubMedCrossRef
Metadaten
Titel
Bevacizumab (Avastin) treatment in patients with retinal angiomatous proliferation
verfasst von
Sandra Joeres
Florian M. A. Heussen
Tobias Treziak
Silvia Bopp
Antonia M. Joussen
Publikationsdatum
01.11.2007
Verlag
Springer-Verlag
Erschienen in
Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 11/2007
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-007-0580-y

Weitere Artikel der Ausgabe 11/2007

Graefe's Archive for Clinical and Experimental Ophthalmology 11/2007 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Open Access 22.02.2024 | Peeling | Originalien

Selektive Vitalfarbstoffe in der Makulachirurgie

Erhöhen sie die Wahrscheinlichkeit der intraoperativen ILM-Identifizierung auch bei einem erfahrenen Operateur?

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.